Zoetis Inc. (NYSE:ZTS) Shares Acquired by Leelyn Smith LLC

Leelyn Smith LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,689 shares of the company’s stock after acquiring an additional 909 shares during the quarter. Leelyn Smith LLC’s holdings in Zoetis were worth $4,238,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the 3rd quarter valued at $33,000. Quarry LP raised its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Finally, Fortitude Family Office LLC lifted its position in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on ZTS. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Stock Performance

NYSE ZTS opened at $176.98 on Friday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The business has a fifty day moving average of $185.62 and a 200-day moving average of $180.53. The stock has a market cap of $79.85 billion, a price-to-earnings ratio of 33.27, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.